| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
SCR130 (7-21 μM; 48 hours) increases in both early and late apoptotic cell counts. Through both internal and external routes, SCR130 causes apoptosis. p-p53, BCL2, and MCL1 expression are all upregulated by SCR130, along with CYTOCHROME C, BAX, and BAK. Increased expression of the FAS and SMAC-DIABLO proteins, as well as caspase 8 activation, have been reported[1]. The IC50 values of SCR130 (48 hours) in Reh, HeLa, CEM, Nalm6, and N114 cells are 14.1 μM, 5.9 μM, 6.5 μM, 2.2 μM, and 11 μM, respectively. These results indicate that SCR130 is cytotoxic]. By causing increased cell death when co-administered in Reh and Nalm6 cell lines, SCR130 can magnify the effects of radiation (0.5 and 1 Gy)[1]. Unrepaired DNA breaks accumulate when SCR130 inhibits the endogenous NHEJ. DNA double-strand breaks (DSBs) accumulate as a result of treatment with SCR130, which inhibits endogenous NHEJ and triggers apoptotic pathways, ultimately leading to cell death[1].
|
|---|---|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: Reh cells Tested Concentrations: 7 μM, 14 μM, and 21 μM Incubation Duration: 48 hrs (hours) Experimental Results: demonstrated a concentration-dependent increase in the number of late and early apoptotic cells. Western Blot Analysis[1] Cell Types: Reh cells Tested Concentrations: 7 μM, 14 μM, and 21 μM Incubation Duration: 48 hrs (hours) Experimental Results: Revealed a concentration-dependent increase in levels of pATM and activation of p53 through phosphorylation. |
| References |
[1]. Ujjayinee Ray, et al. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics. Mol Carcinog. 2020 Jun;59(6):618-628.
|
| Molecular Formula |
C19H13CL2N3O2S
|
|---|---|
| Molecular Weight |
418.30
|
| CAS # |
2377858-38-1
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
ClC1C=CC(=CC=1)C1CC(C2C=CC(=CC=2)Cl)=NC21C(NC(NC2=O)=S)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (239.06 mM )
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3906 mL | 11.9531 mL | 23.9063 mL | |
| 5 mM | 0.4781 mL | 2.3906 mL | 4.7813 mL | |
| 10 mM | 0.2391 mL | 1.1953 mL | 2.3906 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
